METHOD OF TREATING A SKIN CONDITION
An improved method of treating a skin barrier condition is disclosed. The method involves identifying a target portion of skin on a person where treatment is desired and applying a low-pH composition to the target portion of skin. The low-pH composition contains an effective amount of a vitamin B3 compound and has a pH of less than 5.0.
The present disclosure is directed generally to a method of treating the symptoms of a skin barrier condition. More specifically, the present disclosure is directed to a method of treating the symptoms of psoriasis and/or atopic dermatitis with an effective amount of a vitamin B3 compound in a low-pH composition.
BACKGROUNDSkin is the first line of defense against environmental insults that would otherwise damage sensitive underlying tissue and organs. For example, skin maintains a relatively water-impermeable barrier between an organism and its environment to prevent dehydration. Additionally, skin plays a key role in a person's physical appearance. Generally, most people desire to have healthy skin that looks healthy and maintains adequate barrier protection. However, a variety of intrinsic and extrinsic factors can lead to a decline in skin appearance and barrier function. For example, skin conditions such as psoriasis and atopic dermatitis (e.g., eczema) can result in itchy, red, and/or scaly patches of skin that impair the ability of skin to provide adequate barrier function.
Numerous agents, both natural and synthetic, are known for use in skin care compositions marketed to treat various skin conditions, especially those associated with psoriasis and atopic dermatitis. One example of a well-known skin care agent used in cosmetic skin agents is niacinamide. U.S. Pat. No. 5,833,998 discloses the use of niacinamide for regulating the oily/shiny appearance on skin, and U.S. Pat. No. 5,968,528 discloses the use of niacinamide for regulating the signs of skin aging.
In some instances, the combination of niacinamide and other skin agents has been disclosed. For example, US 2012/0121534 and U.S. Pat. No. 5,053,230 disclose compositions for promoting the growth of skin cells to improve the appearance of wrinkled skin. The compositions in the '534 application and '230 patent are disclosed as essentially being growth media for stimulating growth or promoting trophism in skin cells. However, it was not recognized that using a low pH skin care composition comprising niacinamide may alleviate symptoms of psoriasis and/or atopic dermatitis, thereby improving skin barrier function and skin appearance.
Typically, cosmetic compositions are formulated to have a slightly acidic to neutral pH (i.e., from 4.0-7.0) which is believed to improve the stability of certain ingredients in the composition (e.g., niacinamide, salicylates, and neutralized thickeners). However, formulating a skin care composition at a lower pH (e.g., 1.0-4.0) may bolster the acid mantle of the skin, provide flexibility in other types of skin agents that can be included in the composition, and/or provide an exfoliation benefit. Accordingly, it would be desirable to provide a low pH skin care composition that includes niacinamide for improving skin barrier function and skin appearance.
SUMMARYA method of treating a skin barrier condition is provided herein. The method involves identifying a target portion of skin on a person in need of treatment, and then applying a low-pH composition to the target portion of skin during a treatment period. The low-pH composition contains an effective amount of a vitamin B3 compound and has a pH of less than 5.0.
The FIGURE is a bar chart illustrating the synergistic effect of niacinamide and low pH on the level of normalized S100-A7 [SEQ ID NO: 2].
The undesirable symptoms of psoriasis and atopic dermatitis are well known. However, it has now been discovered that using niacinamide at low-pH may be useful for treating symptoms of these and other skin barrier conditions. Surprisingly, it has also been discovered that the combination of niacinamide and low pH appears to provide a synergistic reduction in S100-A7 [SEQ ID NO: 2], which is a protein believed to play an important role in causing symptoms associated psoriasis, atopic dermatitis, and other skin barrier disorders.
Reference within the specification to “embodiment(s)” or the like means that a particular material, feature, structure and/or characteristic described in connection with the embodiment is included in at least one embodiment, optionally a number of embodiments, but it does not mean that all embodiments incorporate the material, feature, structure, and/or characteristic described. Furthermore, materials, features, structures and/or characteristics may be combined in any suitable manner across different embodiments, and materials, features, structures and/or characteristics may be omitted or substituted from what is described. Thus, embodiments and aspects described herein may comprise or be combinable with elements or components of other embodiments and/or aspects despite not being expressly exemplified in combination, unless otherwise stated or an incompatibility is stated.
In all embodiments, all percentages are by weight of the cosmetic composition, unless specifically stated otherwise. All ratios are weight ratios, unless specifically stated otherwise. All ranges are inclusive and combinable. The number of significant digits conveys neither a limitation on the indicated amounts nor on the accuracy of the measurements. All numerical amounts are understood to be modified by the word “about” unless otherwise specifically indicated. Unless otherwise indicated, all measurements are understood to be made at approximately 25° C. and at ambient conditions, where “ambient conditions” means conditions under about 1 atmosphere of pressure and at about 50% relative humidity. All numeric ranges are inclusive of narrower ranges; delineated upper and lower range limits are interchangeable to create further ranges not explicitly delineated.
The compositions of the present invention can comprise, consist essentially of, or consist of, the essential components as well as optional ingredients described herein. As used herein, “consisting essentially of” means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods. As used in the description and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
SEQUENCE LISTINGA sequence listing that sets forth the nucleotide sequence for S100 calcium binding protein A7 (“S100A7”) [SEQ ID NO: 1] and protein S100-A7 [SEQ ID NO: 2] are being filed concurrently with the present application as an ASCII text file titled “15304P_seq_list_ST25”. This ASCII text file was created on Jun. 26, 2018 and is approximately 4.94 KB in size. In accordance with MPEP § 605.08 and 37 CFR § 1.52(e), the subject matter in the ASCII text file is incorporated herein by reference.
Definitions“Apply” or “application”, as used in reference to a composition, means to apply or spread the compositions of the present invention onto a human skin surface such as the epidermis.
“Cosmetic agent” means any substance, as well any component thereof, intended to be rubbed, poured, sprinkled, sprayed, introduced into, or otherwise applied to a mammalian body or any part thereof to provide a cosmetic effect. Cosmetic agents may include substances that are Generally Recognized as Safe (GRAS) by the US Food and Drug Administration, food additives, and materials used in non-cosmetic consumer products including over-the-counter medications.
“Effective amount” means an amount of a compound or composition sufficient to significantly induce a positive benefit to keratinous tissue over the course of a treatment period. The positive benefit may be a health, appearance, and/or feel benefit, including, independently or in combination, the benefits disclosed herein. In a specific example, an effective amount of a vitamin B3 compound is an amount sufficient to improve the health and/or appearance of psoriatic skin during a treatment period. In some instances, an effective amount may be demonstrated using ex vivo and/or in vitro methods.
“Improve the appearance of” means providing a measurable, desirable change or benefit in skin appearance, which may be quantified, for example, by a decrease in redness, inflammation, and/or plaque scales.
“Low pH” means a pH of less than 5.0 (e.g., 1.5 to 5.0 (exclusive); 2.0 to 4.5, 2.5 to 4.0, or about 3.5). A suitable method of determining the pH of a composition is described in more detail below.
“Neutral pH” means a pH of 5.0 to 8.0.
“Safe and effective amount” means an effective amount of an ingredient that is low enough to avoid serious side effects (within the scope of sound medical judgment).
“Skin care” means regulating and/or improving a skin condition. Some nonlimiting examples include improving skin appearance and/or feel by providing a smoother, more even appearance and/or feel; increasing the thickness of one or more layers of the skin; improving the elasticity or resiliency of the skin; improving the firmness of the skin; and reducing the oily, shiny, and/or dull appearance of skin, improving the hydration status or moisturization of the skin, improving the appearance of fine lines and/or wrinkles, improving skin exfoliation or desquamation, plumping the skin, improving skin barrier properties, improve skin tone, reducing the appearance of redness or skin blotches, and/or improving the brightness, radiancy, or translucency of skin.
“Skin care active” means a compound or combination of compounds that, when applied to skin, provide an acute and/or chronic benefit to skin or a type of cell commonly found therein. Skin care actives may regulate and/or improve skin or its associated cells (e.g., improve skin elasticity, hydration, skin barrier function, and/or cell metabolism).
“Skin care composition” means a composition that includes a skin care active and regulates and/or improves skin condition.
“Synergy” and variations thereof mean a bilirubin degrading effect provided by using niacinamide in combination with a low-pH composition that is more than the predicted additive effect of the vitamin B3 compound and low pH.
“Treatment period,” as used herein, means the length of time and/or frequency that a material or composition is applied to a target skin surface.
“Vehicle control” means a negative control that is identical to the test composition except that it does include the particular active(s) of interest (e.g., does not contain a vitamin B3 compound).
Composition
The skin care compositions herein are intended for topical application to human skin for improving the appearance and/or function of psoriatic skin. The compositions herein include an effective amount of a vitamin B3 compound and have a pH of less than 5.0 (e.g., less than 4.5, 4.0, 3.5, 3.0, 2.5 or even 2.0 or less). The compositions are formed by mixing the vitamin B3 compound with a dermatologically acceptable carrier, which may be done using conventional methods known to those skilled in the art. The compositions may optionally include one or more skin actives of the type commonly included in skin care compositions of the type. The compositions may be cosmetic compositions, pharmaceutical compositions, or cosmeceutical compositions, and may be provided in various product forms, including, but are not limited to, solutions, suspensions, lotions, creams, gels, toners, sticks, sprays, aerosols, ointments, cleansing liquid washes and solid bars, pastes, foams, mousses, shaving creams, wipes, strips, patches, electrically-powered patches, hydrogels, film-forming products, facial and skin masks (with and without insoluble sheet), and the like. The composition form may follow from the particular dermatologically acceptable carrier chosen, if present in the composition.
Vitamin B3 Compound
The compositions of the present invention include a safe and effective amount of a vitamin B3 compound. In addition to treating one or more symptoms of psoriasis and/or atopic dermatitis, the vitamin B3 compound may also be useful for regulating other skin condition, for example, as described in U.S. Pat. No. 5,939,082. The compositions herein may contain 0.01% to 15%, by weight, of the vitamin B3 compound, based on the weight or volume of the composition (e.g., 0.1% to 10%, 0.1% to 3%, 0.5% to 8%, 1% to 5%, or even 2% to 4%).
As used herein, “vitamin B3 compound” means a compound having the formula:
R is CONH2 (i.e., niacinamide), COOH (i.e., nicotinic acid) or CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
Exemplary derivatives of vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid (e.g., tocopheryl nicotinate, myristyl nicotinate) nicotinamide riboside, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide, and niacinamide N-oxide.
Dermatologically Acceptable Carrier
The compositions herein include a dermatologically acceptable carrier (which may be referred to as a “carrier”). The phrase “dermatologically acceptable carrier” means that the carrier is suitable for topical application to the keratinous tissue, has good aesthetic properties, is compatible with the actives in the composition, and will not cause any unreasonable safety or toxicity concerns. In one embodiment, the carrier is present at a level of from about 50% to about 99%, about 60% to about 98%, about 70% to about 98%, or, alternatively, from about 80% to about 95%, by weight of the composition.
The carrier can be in a wide variety of forms. In some instances, the solubility or dispersibility of the components (e.g., extracts, sunscreen active, additional components) may dictate the form and character of the carrier. Non-limiting examples include simple solutions (e.g., aqueous or anhydrous), dispersions, emulsions, and solid forms (e.g., gels, sticks, flowable solids, or amorphous materials). In some instances, the dermatologically acceptable carrier is in the form of an emulsion. The emulsion may have a continuous aqueous phase (e.g., an oil-in-water or water-in-oil-in-water emulsion) or a continuous oil phase (e.g., water-in-oil or oil-in-water-in-oil emulsion). The oil phase of the present invention may comprise silicone oils, non-silicone oils such as hydrocarbon oils, esters, ethers, and mixtures thereof. The aqueous phase typically comprises water and water-soluble ingredients (e.g., water-soluble moisturizing agents, conditioning agents, anti-microbials, humectants and/or other skin care actives). However, in some instances, the aqueous phase may comprise components other than water, including but not limited to water-soluble moisturizing agents, conditioning agents, anti-microbials, humectants and/or other water-soluble skin care actives. In some instances, the non-water component of the composition comprises a humectant such as glycerin and/or other polyol(s).
In some instances, the compositions herein are in the form of an oil-in-water (“O/W”) emulsion that provides a sensorial feel that is light and non-greasy. Suitable O/W emulsions herein may include a continuous aqueous phase of more than 50% by weight of the composition, and the remainder being the dispersed oil phase. The aqueous phase may include 1% to 99% water, based on the weight of the aqueous phase, along with any water soluble and/or water miscible ingredients. In these instances, the dispersed oil phase will typically be present at less than 30% by weight of composition (e.g., 1% to 20%, 2% to 15%, 3% to 12%, 4% to 10%, or even 5% to 8%) to help avoid some of the undesirable feel effects of oily compositions. The oil phase may include one or more volatile and/or non-volatile oils (e.g., botanical oils, silicone oils, and/or hydrocarbon oils). Some nonlimiting examples of oils that may be suitable for use in the present compositions are disclosed in U.S. Pat. No. 9,446,265 and U.S. Publication No. 2015/0196464.
The carrier may contain one or more dermatologically acceptable, hydrophilic diluents. As used herein, “diluent” includes materials in which the vitamin B3 compound can be dispersed, dissolved, or otherwise incorporated. Hydrophilic diluents include water, organic hydrophilic diluents such as lower monovalent alcohols (e.g., C1-C4) and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., molecular weight of 200 to 600 g/mole), polypropylene glycol (e.g., molecular weight of 425 to 202.5 g/mole), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers and combinations thereof.
Emulsifier
When the dermatologically acceptable carrier is in the form of an emulsion, it may be desirable to include art emulsifier to provide a stable composition (e.g., does not phase separate). When included, the emulsifier may be present at an amount of 0.1% to 10% (e.g., 1% to 5%, or 2%-4%). Emulsifiers may be nonionic, anionic or cationic. Some non-limiting examples of emulsifiers that may be suitable for use herein are disclosed in U.S. Pat. Nos. 3,755,560; 4,421,769; and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).
Thickeners
In some instances, it may be desirable to use thickeners that tolerate a lower range of pH. For example, neutralized thickeners may degrade at lower pH and thus may not impart the desired thickening or feel properties to the composition. On the other hand, fatty alcohol thickeners such as cetyl alcohols and stearyl alcohols are generally stable at low pH (e.g., pH of less than 5.0 or even between a pH of about 2.5 to about 4.0), and thus may be particularly suited for use in the low pH compositions herein. Accordingly, the present compositions may be free or substantially free of neutralized thickeners and/or may have from 0.1% to 10% (e.g., from about 0.5% to about 8%, from about 1.0% to about 5%, or even from about 2% to about 4%) of a fatty alcohol thickener.
Other Optional Ingredients.
The present composition may optionally include one or more additional ingredients commonly used in cosmetic compositions (e.g., colorants, skin care actives, anti-inflammatory agents, sunscreen agents, emulsifiers, buffers, rheology modifiers, combinations of these and the like), provided that the additional ingredients do not undesirably alter the skin health or appearance benefits provided by the present compositions. The additional ingredients, when incorporated into the composition, should be suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, and the like. Some nonlimiting examples of additional actives include vitamins, minerals, peptides and peptide derivatives, sugar amines, sunscreens, oil control agents, particulates, flavonoid compounds, hair growth regulators, anti-oxidants and/or anti-oxidant precursors, preservatives, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizing agents, exfoliating agents, skin lightening agents, sunless tanning agents, lubricants, anti-acne actives, anti-cellulite actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols and/or plant hormones, N-acyl amino acid compounds, antimicrobials, and antifungals. Other non-limiting examples of additional ingredients and/or skin care actives that may be suitable for use herein are described in U.S. Publication Nos. 2002/0022040; 2003/0049212; 2004/0175347; 2006/0275237; 2007/0196344; 2008/0181956; 2008/0206373; 2010/00092408; 2008/0206373; 2010/0239510; 2010/0189669; 2010/0272667; 2011/0262025; 2011/0097286; US2012/0197016; 2012/0128683; 2012/0148515; 2012/0156146; and 2013/0022557; and U.S. Pat. Nos. 5,939,082; 5,872,112; 6,492,326; 6,696,049; 6,524,598; 5,972,359; and 6,174,533.
When including optional ingredients in the compositions herein, it may be desirable to select ingredients that do not form complexes or otherwise undesirably interact with other ingredients in the composition at low pH, especially pH sensitive ingredients like niacinamide, salicylates and peptides. In some instances, it may be desirable to select skin care actives that function via different biological pathways so that the actives do not interfere with one another, which could reduce the efficacy of both agents. When present, the optional ingredients may be included at amounts of from 0.0001% to 50%; from 0.001% to 20%; or even from 0.01% to 10% (e.g., 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1%), by weight of the composition.
Methods of UseThe low-pH compositions herein include an effective amount of a vitamin B3 compound and are formulated for topical application to skin. The method involves identifying a target portion of skin on a person in need of treatment or where treatment is desired (e.g., skin that is exhibiting impaired barrier function) and applying the low-pH composition to the target portion of skin. The target portion of skin may be on a facial skin surface such as the forehead, perioral, chin, periorbital, nose, and/or cheek) or another part of the body (e.g., hands, arms, legs, back, chest). The target portion of skin may be identified according to known methods of identifying skin with impaired barrier function. For example, the target portion of skin may be identified as needing treatment if it exhibits signs of psoriasis or atopic dermatitis (redness, itchiness, painfulness, inflammation, plaques, scales, etc.). In another example, the target portion of skin may be identified as needing treatment if it exhibits a trans-epidermal water loss (TEWL) that exceeds a threshold level. In still another example, the target portion of skin may be identified as needing treatment if expression of S100A7 [SEQ ID NO: 1] is greater than a threshold value, for example, as demonstrated by a high level of S100-A7 [SEQ ID NO: 2]. In a further example, a target portion of skin may be selected that does not currently exhibit signs of reduced barrier function, but the user desires to provide a preventative benefit, especially if the target portion of skin has previously exhibited signs of reduced barrier function.
In some instances, the method of treating a skin barrier condition involves selecting an effective amount of a vitamin B3 compound and a suitable pH for a skin care composition that will provide a synergistic reduction in S100-A7 [SEQ ID NO: 2]. The selected amount of vitamin B3 can be combined with a dermatologically acceptable carrier to make the skin care composition at the selected pH. The resulting skin composition is then provided to person in need of treatment, for example, via a retail store or direct-to-consumer sale. In this example, the effective amount of vitamin B3 compound and/or pH of the skin composition may be selected by determining their ability to synergistically reduce S100-A7 [SEQ ID NO: 2] in at least one of an in vitro assay, ex vivo assay, of in vivo assay.
The composition may be applied locally to the target portion of skin in need of treatment and, if desired, to the surrounding skin at least once a day, twice a day, or on a more frequent daily basis, during a treatment period. When applied twice daily, the first and second applications are separated by at least 1 to 12 hours. Typically, the composition is applied in the morning and/or in the evening before bed. When used according to the methods herein, the present compositions may improve the appearance and/or barrier function of skin, for example, by reducing redness, inflammation, itchiness, pain, dry/flaky skin, trans-epidermal water loss, the size and/or number of psoriatic plaques, and/or the level of S100-A7 [SEQ ID NO: 2]).
The treatment period is ideally of sufficient time for the vitamin B3 compound present in the low-pH composition to improve the appearance and/or barrier function of a target portion of skin. The treatment period typically lasts for at least 1 week (e.g., about 2 weeks, 4 weeks, 8 weeks, or even 12 weeks). In some instances, the treatment period may extend over multiple months (i.e., 3-12 months). In some instances, the composition is applied most days of the week (e.g., at least 4, 5 or 6 days a week), at least once a day or even twice a day during a treatment period of at least 2 weeks, 4 weeks, 8 weeks, or 12 weeks.
The step of applying the composition may be accomplished by localized application. In reference to application of the composition, the terms “localized”, “local”, or “locally” mean that the composition is delivered to the targeted area (e.g., a psoriatic plaque) while minimizing delivery to skin surfaces where treatment is not desired. The composition may be applied and lightly massaged into an area of skin. The form of the composition or the dermatologically acceptable carrier should be selected to facilitate localized application. While certain embodiments herein contemplate applying a composition locally to an area, it will be appreciated that compositions herein can be applied more generally or broadly to one or more skin surfaces. In certain embodiments, the compositions herein may be used as part of a multi-step beauty regimen, wherein the present composition may be applied before and/or after one or more other compositions.
EXAMPLEThis example demonstrates the unexpected ability of a low-pH composition comprising niacinamide to potentially improve the appearance and/or barrier function of skin suffering from psoriasis, atopic dermatitis, and/or skin barrier conditions. In this example, changes in the level of S100-A7 [SEQ ID NO: 2] are used as a surrogate for the effect of the low-pH, niacinamide containing composition on skin barrier function.
Skin care agents that can downregulate S100A7 [SEQ ID NO: 1] are considered a promising approach to treating symptoms of psoriasis, atopic dermatitis, and other skin barrier conditions. S100A7 [SEQ ID NO: 1], also called psoriasin, is a member of the S100 multigene family that is encoded in the epidermal differentiation complex on chromosome 1q21. S100A7 [SEQ ID NO: 1] is highly expressed in epidermal hyperproliferative disease, and overexpression of S100A7 [SEQ ID NO: 1] is believed to contribute to the symptoms of psoriasis (Ekman, et al., “Overexpression of Psoriasin (S100A7) Contributes to Dysregulated Differentiation in Psoriasis,” Acta Derm Venereol, 2017 Apr. 6, 97(4); 441-448). S100A7 [SEQ ID NO: 1] has also been reported to be upregulated in cases of atopic dermatitis and other skin barrier conditions (Glaser, et al., (2008); “The Antimicrobial Protein Psoriasin (S100A7) Is Upregulated in Atopic Dermatitis and after Experimental Skin Barrier Disruption” Journal of Investigative Dermatology, 129(3), 641-649). Thus, it is believed, without being limited by theory, that inhibiting the expression of S100A7 [SEQ ID NO: 1] and/or reducing the level of S100-A7 [SEQ ID NO: 2] will alleviate symptoms of psoriasis, atopic dermatitis, and other skin barrier conditions associated with overexpression of S100A7 [SEQ ID NO: 1] and/or accumulation of 5100-A7 [SEQ ID NO: 2].
In this example, a low-pH composition (pH 2.5) comprising niacinamide at 5% (w/v) was tested to determine its ability to regulate the expression of S100A7 [SEQ ID NO: 1]. A vehicle control was used in this Example as the negative control. The expression level of S100A7 [SEQ ID NO: 1] was determined by measuring the normalized amount of protein S100-A7 [SEQ ID NO: 2] present in each sample.
Sample Prep and Test MethodKeratinocytes from human donors (available from Lonza, N.J.) are cultivated with Complete KBM Gold media until they reached 70-80% confluency. The keratinocytes are then subcultured per manufacturer's recommendations and used at either passage 1 or 2. For growth of keratinocytes on de-epidermized dermis (DED), two media are used. Medium 1 is used for the first three days while the cultures remained submerged and Medium 2 is used when cultures are raised to the air-liquid interface and then until the time of collection.
Medium 1 consists of: Dulbecco's Modified Eagle Medium (DMEM) and Ham's F-12 Nutrient Mixture at a ratio of 3:1, followed by the addition of Hyclone Cosmic Calf Serum (5%), Hydrocortisone (0.4 μg/ml), epidermal growth factor (0.02 mg/ml), transferrin (3 mg/me, insulin (5 μg/ml), cholera toxin (0.02 μg/ml), triiodothyronine (2×10−11 M), adenine (0.18 mM), sodium pyruvate 1×, GlutaMax 1× (Invitrogen), CaCl2 (300 uM), 1×CD lipid concentrate 300 μM, fibroblast growth factor 7 (FGF-7) (10 ng/ml), and penicillin/streptomycin 1×.
Medium 2 consists of: medium 1 modified with the addition of 1% serum and removal of FGF-7 and 1 mM CaCl2. Medium 1 is used for two days while the cultures remain submerged and Medium 2 is used for cultures raised to the air-liquid interface.
De-epidermized dermis (DED) is prepared by removing fat from the skin sample with a scalpel, cutting the skin into squares measuring 1.25 cm2, and placing the samples in 1M NaCl plus 10× penicillin/streptomycin. The sample is incubated overnight at 37° C. The following day, the epidermis is carefully peeled off with forceps and dermal tissue is stored in phosphate-buffered saline (PBS) plus 2× penicillin/streptomycin at 4° C. until ready for use.
Approximately 5×105 keratinocytes in 50 μl of Medium 1 are pipetted into 8 mm cloning cylinders placed atop DEDs. 2 ml of Medium 1 is added to the bottom of the 6-well plate containing the transwell. The plates are incubated overnight at 33° C. in 5% CO2 and 55% RH. The following day, the cloning cylinders are removed and cultures are submerged in Medium 1. At three days, cultures are raised to the air-liquid interface in Medium 2.
At day 7 at the air-liquid interface, the cultures are treated topically with one of four test compositions (a vehicle control at pH 2.5 or pH 5, or a 5% (w/v) niacinamide composition at pH 2.5 or pH 5), and one sample is left untreated, for a total of five test legs. Each test leg has four replicates. The pH of each sample can be adjusted using 1M HCl pH titration, for example, performed separately before the experiment set up to determine how much 1M HCl is needed for each leg to achieve targeting pH level. Cultures are dosed topically twice per day for 5 days. The keratinocytes are isolated from each culture on day 5 using 3.8% ammonium thiocyanate. The keratinocytes are weighed and then flash-frozen for mass spectrometry and protein level determination.
S100-A7 Protein MeasurementFrozen keratinocyte samples are thawed. 20 ul/mg (wet weight) of keratinocytes are placed in a solution of 4% sodium dodecyl sulphate, 0.1 M dithiothreitol, and 150 mM Tris (pH 7.5) and sonicated for 30 minutes to lyse the cells. Filter-aided sample preparation is used to prepare peptides for Liquid Chromatography-Mass Spec analysis. Lysate prepared above is centrifuged for 10 minutes at 18,000×g to clarify, and the supernatant is then mixed in a 1:10 ratio with 180 μl 8M Urea, 150 mM Tris (pH 8.5). This mixture is placed into YM-30 centrifugal filter unit (Millipore) and centrifuged for 10 minutes at 14,000×g. Proteins are captured on the filter. We then add 200 μl 8M Urea, 150 mM Tris pH 8.5 to the filter and spin as above to wash. 100 μl 50 mM iodoacetamide is added to the filter and incubated for 30 minutes at ambient temperature in the dark to alkylate cysteine residues. This buffer is then centrifuged through the filter and followed with 3 wash steps of 200 μl 8M Urea, 150 mM Tris pH 8.5 as above. This is followed by 3 wash steps of 200 μl 100 mM Ammonium bicarbonate. 40 μl of 0.5 μg/μl Trypsin/LysC (Promega) in 100 mM Ammonium bicarbonate is added to the filter. Filter units are then incubated 16 hours in a 37° C. incubator. Resulting peptides are collected in clean tubes by centrifugation as above. Synthetic isotopically labeled internal standards (e.g., from New England Peptide) are added in equal amounts to each sample. These standards include the peptide sequence GTNYLADVFEK, with the C-terminal lysine labeled using 13C(6)15N(2). Peptides are analyzed using an Agilent 1690 Infinity LC system coupled to an Agilent 6490 QQQ mass spectrometer (or equivalent) against a scheduled multiple reaction monitoring method. Peptides are loaded onto an Agilent Zorbax RRHD Eclipse Plus 95 Å C18, 2.1×150 mm, 1.8 μm, 1200 bar column heated to 50° C. Mobile phases are A: 0.1% Formic acid in water and B: 0.1% Formic Acid, 90% Acetonitrile, 9.9% water. The flow rate is 0.4 ml/min. The dynamic MRM method contains 4 transitions for the GTNYLADVFEK peptide. These transitions are based on the doubly-charged precursor 628.8115 m/z for the endogenous peptide and 632.8186 m/z for the labeled internal standard. Peaks are manually verified using the Skyline software and peak areas are exported for further normalization and analysis.
The results of the test are summarized below in Table 1. The protein values shown are the averaged amount of S100-A7 [SEQ ID NO: 2] detected for the 4 replicates in each test leg. The measured protein amount is the log 2 normalized intensity after fitting nonlinear regression models using the default settings for the MSstats statistical analysis package. The delta versus untreated value is calculated by subtracting the measured protein amount for each leg from the measured protein amount for the untreated leg. The normalized protein amount reflects the amount of measured S100-A7 normalized to the untreated sample, which is assigned a baseline value of 100. The p-value is determined by combined pairwise ANOVA comparison of the experimental conditions corrected for multiple hypothesis testing using the Benjamini & Hochberg method. A p-value of 0.1 or less is considered statistically significant.
Table 2 and
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm”.
Every document cited herein, including any cross referenced or related patent or application and any patent application or patent to which this application claims priority or benefit thereof, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims
1. A method of treating a skin barrier condition, comprising:
- a) identifying a target portion of skin on a person where treatment is desired; and
- b) applying a low-pH composition to the target portion of skin during a treatment period, wherein the low-pH composition comprises an effective amount of niacinamide and has a pH of about 3.5 to less than 4.0 and reduces the amount of S100-A7 [SEQ ID NO: 2] according to the S100-A7 Protein Measurement method.
2. The method of claim 1, wherein the composition comprises about 0.01% to about 10% of the niacinamide.
3. The method of claim 1, wherein the composition downregulates S100A7 [SEQ ID NO: 1]
4. The method of claim 1, wherein the synergistic reduction in 5100-A7 [SEQ ID NO: 2] is at least 10% more than a predicted additive amount of S100-A7 [SEQ ID NO: 2] reduction.
5. The method of claim 1, wherein the composition comprises at least one additional skin care active wherein the at least one additional skin care active comprises vitamins, minerals, peptides, sugar amines, sunscreens, oil control agents, flavonoid compounds, anti-oxidants, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizing agents, exfoliating agents, skin lightening agents, anti-acne agents, anti-wrinkle agents, phytosterols, N-acyl amino acid compounds, antimicrobials, antifungals, or a combination thereof.
6. The method of claim 1, wherein the composition comprises about 0.1% to about 10% of a stable fatty alcohol thickener.
7. The method of claim 6, wherein the stable fatty alcohol thickener comprises cetyl alcohols, stearyl alcohols, or a combination thereof.
8. The method of claim 1, wherein the skin harrier condition is psoriasis or atopic dermatitis.
9. The method of claim 1, wherein the low-pH composition is free of neutralized thickeners.
10. A method of treating psoriasis or atopic dermatitis, comprising:
- a) determining an effective amount of niacinamide and a pH for providing a reduction in the expression of 5100 calcium binding protein A7 [SEQ ID NO: 1] by contacting keratinocytes with a composition comprising niacinamide and having a pH of about 3.5 to less than 4.0, and measuring the change in the amount of 5100-A7 [SEQ ID NO: 2];
- b) combining the effectives amount of niacinamide with a dermatologically acceptable carrier to make a skin care composition at the determined pH;
- c) providing the skin care composition to a person exhibiting a symptom of psoriasis or atopic dermatitis; and
- d) applying the composition to a portion of skin exhibiting the symptom of psoriasis or atopic dermatitis.
11. The method of claim 10, wherein the amount of niacinamide is between 0.01% and 10%, by weight of the composition.
12. The method of claim 10, wherein the skin care composition comprises at least one additional skin care active.
13. The method of claim 10, wherein the composition reduces the S100-A7 level by at least 10% compared to a corresponding neutral pH composition.
14. The method of claim 10, wherein the low-pH composition is free of neutralized thickeners.
Type: Application
Filed: Mar 7, 2022
Publication Date: Jun 23, 2022
Inventors: Tomohiro (NMN) HAKOZAKI (Cincinnati, OH), Leo Timothy LAUGHLIN, II (Mason, OH), Jason Martin WINGET (Mason, OH), Teresa DiCOLANDREA (Wyoming, OH)
Application Number: 17/688,126
